Related Experiment Video

Updated: Aug 25, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Novel clinical trials in androgen-independent prostate cancer

James Gulley1, William Dahut

  • 1National Cancer Institute, Bethesda, MD 20892, USA. gulleyj@mail.nih.gov

Clinical Prostate Cancer
|March 30, 2004
PubMed

Insights

Novel drugs targeting apoptosis, angiogenesis, and growth factor pathways are being investigated to improve survival for androgen-independent prostate cancer. These agents, alone or combined with chemotherapy, aim to enhance quality of life for patients with metastatic prostate cancer.

Area of Science:

  • Oncology
  • Pharmacology
  • Cancer Biology

Background:

  • Current treatments for androgen-independent prostate cancer offer limited survival benefits.
  • Metastatic prostate cancer remains a significant clinical challenge.
  • There is a critical need for more effective therapeutic strategies.

Purpose of the Study:

  • To review novel therapeutic agents and drug combinations for androgen-independent prostate cancer.
  • To discuss emerging drug targets including apoptosis, antiangiogenesis, and growth factor signaling.
  • To highlight research into novel agents and their potential role in combination chemotherapy.

Main Methods:

  • Review of preclinical and early clinical trial data for novel prostate cancer drugs.
  • Analysis of therapeutic strategies targeting specific molecular pathways.
  • Examination of drug combinations involving novel agents and chemotherapy.

Main Results:

  • Several novel drugs targeting key cancer pathways are advancing through clinical trials.
  • Combinations of novel agents with chemotherapy show promise for improved efficacy.
  • Targeted therapies aim to enhance survival and quality of life in prostate cancer patients.

Conclusions:

  • Novel agents targeting apoptosis, antiangiogenesis, and growth factor pathways represent a promising frontier.
  • Combination therapies involving novel drugs may offer improved outcomes for metastatic prostate cancer.
  • Continued research into targeted agents is crucial for advancing prostate cancer treatment.

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Related Concept Videos

Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...